Tag Archives: AstraZeneca

AstraZeneca lanza un desafío posdoctoral de I+D global en EXPO 2020 Dubái

El desafío tiene como objetivo ayudar al descubrimiento de avances transformadores en las áreas de enfermedades centrales de AstraZeneca. Las propuestas exitosas asegurarán puestos de investigación posdoctorales totalmente financiados (COMUNICADO DE PRENSA) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), … Read the full press release

AstraZeneca launches a global R&D Postdoctoral Challenge at EXPO 2020 Dubai

The challenge aims at helping the discovery of transformative breakthroughs across AstraZeneca’s core disease areas Successful proposals will secure fully funded postdoctoral research positions (PRESS RELEASE) CAMBRIDGE, 17-Mar-2022 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British-Swedish multinational pharmaceutical and biotechnology … Read the full press release

AstraZeneca reçoit l’approbation de l’UE pour son Saphnelo, le seul nouveau médicament depuis plus d’une décennie pour les patients atteints de lupus érythémateux disséminé

(COMMUNIQUÉ DE PRESSE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON : AZN), une multinationale pharmaceutique et biotechnologique anglo-suédoise , a annoncé l’approbation par l’Union européenne (UE) de son médicament Saphnelo (anifrolumab) en tant que traitement d’appoint pour le traitement des patients … Read the full press release

AstraZeneca receives EU approval for its Saphnelo, the only new medicine in over a decade for patients with systemic lupus erythematosus

(PRESS RELEASE) CAMBRIDGE, 16-Feb-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced an European Union (EU) approval for its Saphnelo (anifrolumab) medicine as an add-on therapy for the treatment of adult patients with … Read the full press release

Transthyretin amyloid cardiomyopathy: Alexion granted an exclusive worldwide licence to develop, manufacture and commercialise NI006 as part of an agreement with Neurimmune AG

Investigational human monoclonal antibody in Phase Ib development for the treatment of transthyretin amyloid cardiomyopathy, a systemic, progressive and fatal condition (PRESS RELEASE) CAMBRIDGE, 7-Jan-2022 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced … Read the full press release

AstraZeneca completes the transfer of Eklira/Tudorza and Duaklir global rights to Covis Pharma Group for $270 million

(PRESS RELEASE) CAMBRIDGE, 5-Jan-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced the completion of the transfer of its global rights to Eklira (aclidinium bromide), popular as Tudorza in the US, and Duaklir … Read the full press release

Covis Pharma takes over AstraZeneca’s COPD medicines Eklira and Duaklir for $270 million

Agreement sharpens AstraZeneca’s focus on priority medicines in Respiratory & Immunology portfolio (PRESS RELEASE) CAMBRIDGE, 1-Nov-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced it sold the global rights of its chronic obstructive … Read the full press release

AL Amyloidosis: Alexion, AstraZeneca Rare Disease, takes over Caelum Biosciences, Inc.

(PRESS RELEASE) CAMBRIDGE, 29-Sep-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish multinational pharmaceutical and biotechnology company, has announced its rare diseases arm Alexion has exercised its option to acquire all remaining equity in Caelum Biosciences, Inc., a Clinical Stage … Read the full press release

AstraZeneca: Exciting ROpel Phase III trial results demonstrate the potential for Lynparza with abiraterone to become a new 1st-line option for patients with metastatic castration-resistant prostate cancer

(PRESS RELEASE) CAMBRIDGE, 24-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced positive high-level results from the PROpel Phase III trial showed AstraZeneca and MSD’s Lynparza (olaparib) in combination with abiraterone demonstrated a … Read the full press release

AstraZeneca, EU agree to end legal proceedings over the delivery of the COVID-19 vaccine Vaxzevria

(PRESS RELEASE) CAMBRIDGE, 3-Sep-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical and biopharmaceutical company, has announced an agreement between the Company and the European Commission has been reached that puts an end of the legal proceedings over … Read the full press release

The only new medicine in over a decade for patients with systemic lupus erythematosus gets Food and Drug Administration (FDA) approval

(PRESS RELEASE) CAMBRIDGE, 2-Aug-2021 — /EuropaWire/ — AstraZeneca (LON: AZN), a British-Swedish science-led biopharmaceutical company, has announced that its Saphnelo (anifrolumab-fnia) has been approved in the US for the treatment of adult patients with moderate to severe systemic lupus erythematosus … Read the full press release

COVID-19 Vaccine AstraZeneca confirmed safe and effective at preventing COVID-19

Increased efficacy with longer inter-dose interval Protection of over 70% starting after a first dose First indication of reduction in disease transmission of up to 67% (PRESS RELEASE) CAMBRIDGE, 3-Feb-2021 — /EuropaWire/ — AstraZeneca (LSE/STO/Nasdaq: AZN), a British–Swedish multinational pharmaceutical … Read the full press release

New EU / AstraZeneca deal to help EU member states access the AZD1222 COVID-19 vaccine at no profit during the pandemic

(PRESS RELEASE) CAMBRIDGE, 14-Aug-2020 — /EuropaWire/ — Global science-led biopharmaceutical company AstraZeneca (LSE/STO/NYSE: AZN) has announced it signed an agreement with the European Commission (EC) for the supply of up to 400 million doses of the AZD1222 COVID-19 vaccine. Building … Read the full press release

AstraZeneca: two trials show long-term efficacy and tolerability of Calquence (acalabrutinib) in chronic lymphocytic leukaemia

ACE-CL-001 trial showed an overall response rate of 97% with a sustained safety profile for previously untreated patients after more than four years In pivotal ASCEND trial, 82% of patients with relapsed or refractory disease treated with Calquence remained progression … Read the full press release

New data from AstraZeneca’s renal medicines will be presented at the 57th European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Virtual Congress

(PRESS RELEASE) CAMBRIDGE, 5-Jun-2020 — /EuropaWire/ — British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca announced it will present new data across continuum of care from its broad renal portfolio during the 57th virtual congress of the European Renal Association – … Read the full press release

Rare disease: Enhertu of AstraZeneca and Daiichi Sankyo now with Orphan Drug Designation in the US for treatment of gastric cancer

(PRESS RELEASE) CAMBRIDGE, 22-May-2020 — /EuropaWire/ — Enhertu, jointly developed by British-Swedish multinational pharmaceutical and biopharmaceutical company AstraZeneca and the second-largest pharmaceutical company in Japan Daiichi Sankyo (Daiichi Sankyo Company, Limited), has just been granted Orphan Drug Designation (ODD) in … Read the full press release

COVID-19: AstraZeneca to start clinical trial to assess Calquence potential in reducing mortality and need for assisted ventilation in patients

The trial, called CALAVI, will assess the effect of Calquence on the exaggerated immune response of patients hospitalised with COVID-19 infection (PRESS RELEASE) CAMBRIDGE, 14-Apr-2020 — /EuropaWire/ — Pharmaceutical giant AstraZeneca to begin a randomised, global clinical trial to assess … Read the full press release

Hyperkalaemia: Japan’s Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma

Hyperkalaemia - Japan’s Ministry of Health, Labour and Welfare has approved AstraZeneca’s Lokelma

(PRESS RELEASE) CAMBRIDGE, 26-Mar-2020 — /EuropaWire/ — Science-led biopharmaceutical group AstraZeneca (LSE/STO/NYSE: AZN) has announced that its Lokelma (sodium zirconium cyclosilicate) is now approved in Japan. It is used for the treatment of patients with hyperkalaemia (elevated levels of potassium … Read the full press release

ChemChina and Sinochem consolidate their agricultural assets to form new holding company, Syngenta Group

(PRESS RELEASE) BASEL, 6-Jan-2020 — /EuropaWire/ — ChemChina and Sinochem announce the creation of Syngenta Group. The new holding company is the consolidation of both companies’ agricultural assets. Mark Patrick, Chief Financial Officer (CFO) and member of the Syngenta Executive … Read the full press release

AstraZeneca will use BenevolentAI’s advanced AI to dive into its disease area expertise and massive datasets to gain insights into the complex disease biology

AstraZeneca / BenevolentAI artificial intelligence collaboration will accelerate drug discovery Potential new drugs discovery in the area of chronic kidney disease and idiopathic pulmonary fibrosis (PRESS RELEASE) CAMBRIDGE / LONDON, 30-Apr-2019 — /EuropaWire/ — New partnership, announced today, by AstraZeneca … Read the full press release

AstraZeneca, Acerta Pharma, MedImmune to present at the 2018 American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego

27 scientific presentations, including long-term data from Calquence in mantle cell lymphoma and updated early-phase trial results in chronic lymphocytic leukaemia New data on six medicines and potential new medicines across a variety of blood cancers demonstrate breadth of haematology portfolio … Read the full press release

AstraZeneca enters into an agreement with Covis Pharma to sell its rights to Alvesco, Omnaris and Zetonna

CAMBRIDGE, 07-Nov-2018 — /EuropaWire/ — AstraZeneca has entered into an agreement with Covis Pharma B.V. (Covis Pharma) to sell its rights to the medicines Alvesco (ciclesonide), used for the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with … Read the full press release

AstraZeneca and Amgen announce US FDA Breakthrough Therapy Designation for tezepelumab in patients with severe asthma

AstraZeneca’s first Breakthrough Therapy Designation for a respiratory medicine Designation based on Phase IIb PATHWAY data that demonstrated tezepelumab significantly reduced asthma exacerbations compared to placebo in severe asthma CAMBRIDGE, 12-Sep-2018 — /EuropaWire/ — AstraZeneca and its partner Amgen Inc. (Amgen) … Read the full press release

AstraZeneca and Merck & Co., Inc. announce positive results from the randomised, double-blinded, placebo-controlled, Phase III SOLO-1 trial of Lynparza (olaparib) tablets

Lynparza met primary endpoint of progression-free survival in women with BRCA-mutated advanced ovarian cancer and showed a safety profile consistent with previous trials AstraZeneca and MSD’s Lynparza is the only PARP inhibitor to demonstrate significant activity in the 1st-line maintenance … Read the full press release

AstraZeneca and MedImmune present results from Phase III clinical trial of moxetumomab pasudotox in patients with hairy cell leukaemia

Trial meets the primary endpoint of durable complete response Majority of patients who had a complete response had no evidence of any remaining detectable cancer cells Phase III clinical trial results served as basis for recent US FDA regulatory submission … Read the full press release

AstraZeneca: US FDA approval for Imfinzi for the treatment of patients with unresectable Stage III non-small cell lung cancer

Imfinzi is the only immunotherapy approved for patients with unresectable Stage III non-small cell lung cancer Imfinzi showed an 11.2 month improvement in median progression-free survival (16.8 months compared to 5.6 months on placebo) CAMBRIDGE, 22-Feb-2018 — /EuropaWire/ — AstraZeneca and … Read the full press release

AstraZeneca: Japan approval for Lynparza (olaparib) tablets for use as a maintenance therapy for patients with platinum-sensitive relapsed ovarian cancer

Lynparza is the first PARP inhibitor approved in Japan Lynparza tablets approved as maintenance treatment for women with platinum-sensitive relapsed ovarian cancer regardless of BRCA mutation status CAMBRIDGE, 22-Jan-2018 — /EuropaWire/ — AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, … Read the full press release

AstraZeneca Phase III PACIFIC trial: Imfinzi demonstrated statistically-significant and clinically-meaningful improvement in PFS

Imfinzi improves progression-free survival (PFS) by more than 11 months compared to standard of care and is the first medicine to show superior PFS in this setting Data presented at the ESMO 2017 Congress follows FDA’s recent Breakthrough Therapy Designation … Read the full press release

AstraZeneca Phase III FLAURA trial supports Tagrisso’s potential as a new standard of care in 1st-line EGFR-mutated lung cancer

Phase III FLAURA trial results show Tagrisso reduced the risk of progression or death by more than half, with consistent benefit across all subgroups, including patients with and without brain metastases Unprecedented median progression-free survival (PFS) of 18.9 months compared … Read the full press release

MedImmune and Sanofi Pasteur to jointly develop and commercialise respiratory syncytial virus monoclonal antibody

LONDON, 03-Mar-2017 — /EuropaWire/ — MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, today announced an agreement to develop and commercialise MEDI8897 jointly. MEDI8897 is a monoclonal antibody (mAb) for the … Read the full press release